MedTrace Logo

A Study to Evaluate MWN109 Injection in Healthy Subjects

NCT06859853 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-04-15

No results posted yet for this study

Summary

This study is a Phase1, randomized, double-blinded, and placebo-controlled study. In each cohort, enrolled participants will be randomized to receive either placebo or MWN109.

Conditions

  • Overweight or Obese

Interventions

DRUG

Placebo

Sub cutaneous injection on the abdomen by a qualified member of study staff.

DRUG

Subcutaneous single and mutiple dose

Sub cutaneous injection on the abdomen by a qualified member of study staff.

Sponsors & Collaborators

  • Shanghai Minwei Biotechnology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Guitao Zhang · Shanghai Minwei Biotechnology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-17
Primary Completion
2025-09-25
Completion
2025-11-25
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06859853 on ClinicalTrials.gov